Global Immunotherapy Drugs for Neuroblastoma Market Growth 2025-2031
The global Immunotherapy Drugs for Neuroblastoma market size is predicted to grow from US$ 50.9 million in 2025 to US$ 67.4 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
United States market for Immunotherapy Drugs for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immunotherapy Drugs for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immunotherapy Drugs for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immunotherapy Drugs for Neuroblastoma players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Immunotherapy Drugs for Neuroblastoma Industry Forecast” looks at past sales and reviews total world Immunotherapy Drugs for Neuroblastoma sales in 2024, providing a comprehensive analysis by region and market sector of projected Immunotherapy Drugs for Neuroblastoma sales for 2025 through 2031. With Immunotherapy Drugs for Neuroblastoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immunotherapy Drugs for Neuroblastoma industry.
This Insight Report provides a comprehensive analysis of the global Immunotherapy Drugs for Neuroblastoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immunotherapy Drugs for Neuroblastoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immunotherapy Drugs for Neuroblastoma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immunotherapy Drugs for Neuroblastoma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immunotherapy Drugs for Neuroblastoma.
This report presents a comprehensive overview, market shares, and growth opportunities of Immunotherapy Drugs for Neuroblastoma market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Immunotherapy Drugs for Neuroblastoma market?
What factors are driving Immunotherapy Drugs for Neuroblastoma market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immunotherapy Drugs for Neuroblastoma market opportunities vary by end market size?
How does Immunotherapy Drugs for Neuroblastoma break out by Type, by Application?
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
United States market for Immunotherapy Drugs for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immunotherapy Drugs for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immunotherapy Drugs for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immunotherapy Drugs for Neuroblastoma players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Immunotherapy Drugs for Neuroblastoma Industry Forecast” looks at past sales and reviews total world Immunotherapy Drugs for Neuroblastoma sales in 2024, providing a comprehensive analysis by region and market sector of projected Immunotherapy Drugs for Neuroblastoma sales for 2025 through 2031. With Immunotherapy Drugs for Neuroblastoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immunotherapy Drugs for Neuroblastoma industry.
This Insight Report provides a comprehensive analysis of the global Immunotherapy Drugs for Neuroblastoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immunotherapy Drugs for Neuroblastoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immunotherapy Drugs for Neuroblastoma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immunotherapy Drugs for Neuroblastoma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immunotherapy Drugs for Neuroblastoma.
This report presents a comprehensive overview, market shares, and growth opportunities of Immunotherapy Drugs for Neuroblastoma market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Dinutuximab
- Naxitamab
- Other
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- United Therapeutics
- Y-mAbs Therapeutics
- EUSA Pharma
- ANI Pharmaceuticals
- Baxter Healthcare
- Ingenus Pharmaceuticals
- Pfizer
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
What is the 10-year outlook for the global Immunotherapy Drugs for Neuroblastoma market?
What factors are driving Immunotherapy Drugs for Neuroblastoma market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immunotherapy Drugs for Neuroblastoma market opportunities vary by end market size?
How does Immunotherapy Drugs for Neuroblastoma break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immunotherapy Drugs for Neuroblastoma Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Immunotherapy Drugs for Neuroblastoma by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Immunotherapy Drugs for Neuroblastoma by Country/Region, 2020, 2024 & 2031
2.2 Immunotherapy Drugs for Neuroblastoma Segment by Type
2.2.1 Dinutuximab
2.2.2 Naxitamab
2.2.3 Other
2.3 Immunotherapy Drugs for Neuroblastoma Sales by Type
2.3.1 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
2.3.2 Global Immunotherapy Drugs for Neuroblastoma Revenue and Market Share by Type (2020-2025)
2.3.3 Global Immunotherapy Drugs for Neuroblastoma Sale Price by Type (2020-2025)
2.4 Immunotherapy Drugs for Neuroblastoma Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Immunotherapy Drugs for Neuroblastoma Sales by Application
2.5.1 Global Immunotherapy Drugs for Neuroblastoma Sale Market Share by Application (2020-2025)
2.5.2 Global Immunotherapy Drugs for Neuroblastoma Revenue and Market Share by Application (2020-2025)
2.5.3 Global Immunotherapy Drugs for Neuroblastoma Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Immunotherapy Drugs for Neuroblastoma Breakdown Data by Company
3.1.1 Global Immunotherapy Drugs for Neuroblastoma Annual Sales by Company (2020-2025)
3.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Company (2020-2025)
3.2 Global Immunotherapy Drugs for Neuroblastoma Annual Revenue by Company (2020-2025)
3.2.1 Global Immunotherapy Drugs for Neuroblastoma Revenue by Company (2020-2025)
3.2.2 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Company (2020-2025)
3.3 Global Immunotherapy Drugs for Neuroblastoma Sale Price by Company
3.4 Key Manufacturers Immunotherapy Drugs for Neuroblastoma Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immunotherapy Drugs for Neuroblastoma Product Location Distribution
3.4.2 Players Immunotherapy Drugs for Neuroblastoma Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA BY GEOGRAPHIC REGION
4.1 World Historic Immunotherapy Drugs for Neuroblastoma Market Size by Geographic Region (2020-2025)
4.1.1 Global Immunotherapy Drugs for Neuroblastoma Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Immunotherapy Drugs for Neuroblastoma Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Immunotherapy Drugs for Neuroblastoma Market Size by Country/Region (2020-2025)
4.2.1 Global Immunotherapy Drugs for Neuroblastoma Annual Sales by Country/Region (2020-2025)
4.2.2 Global Immunotherapy Drugs for Neuroblastoma Annual Revenue by Country/Region (2020-2025)
4.3 Americas Immunotherapy Drugs for Neuroblastoma Sales Growth
4.4 APAC Immunotherapy Drugs for Neuroblastoma Sales Growth
4.5 Europe Immunotherapy Drugs for Neuroblastoma Sales Growth
4.6 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Growth
5 AMERICAS
5.1 Americas Immunotherapy Drugs for Neuroblastoma Sales by Country
5.1.1 Americas Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
5.1.2 Americas Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
5.2 Americas Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
5.3 Americas Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immunotherapy Drugs for Neuroblastoma Sales by Region
6.1.1 APAC Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025)
6.1.2 APAC Immunotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025)
6.2 APAC Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
6.3 APAC Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Immunotherapy Drugs for Neuroblastoma by Country
7.1.1 Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
7.1.2 Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
7.2 Europe Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
7.3 Europe Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma by Country
8.1.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
8.1.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
8.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
8.3 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immunotherapy Drugs for Neuroblastoma
10.3 Manufacturing Process Analysis of Immunotherapy Drugs for Neuroblastoma
10.4 Industry Chain Structure of Immunotherapy Drugs for Neuroblastoma
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immunotherapy Drugs for Neuroblastoma Distributors
11.3 Immunotherapy Drugs for Neuroblastoma Customer
12 WORLD FORECAST REVIEW FOR IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA BY GEOGRAPHIC REGION
12.1 Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Region
12.1.1 Global Immunotherapy Drugs for Neuroblastoma Forecast by Region (2026-2031)
12.1.2 Global Immunotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Immunotherapy Drugs for Neuroblastoma Forecast by Type (2026-2031)
12.7 Global Immunotherapy Drugs for Neuroblastoma Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 United Therapeutics
13.1.1 United Therapeutics Company Information
13.1.2 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 United Therapeutics Main Business Overview
13.1.5 United Therapeutics Latest Developments
13.2 Y-mAbs Therapeutics
13.2.1 Y-mAbs Therapeutics Company Information
13.2.2 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Y-mAbs Therapeutics Main Business Overview
13.2.5 Y-mAbs Therapeutics Latest Developments
13.3 EUSA Pharma
13.3.1 EUSA Pharma Company Information
13.3.2 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 EUSA Pharma Main Business Overview
13.3.5 EUSA Pharma Latest Developments
13.4 ANI Pharmaceuticals
13.4.1 ANI Pharmaceuticals Company Information
13.4.2 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 ANI Pharmaceuticals Main Business Overview
13.4.5 ANI Pharmaceuticals Latest Developments
13.5 Baxter Healthcare
13.5.1 Baxter Healthcare Company Information
13.5.2 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Baxter Healthcare Main Business Overview
13.5.5 Baxter Healthcare Latest Developments
13.6 Ingenus Pharmaceuticals
13.6.1 Ingenus Pharmaceuticals Company Information
13.6.2 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Ingenus Pharmaceuticals Main Business Overview
13.6.5 Ingenus Pharmaceuticals Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Hikma Pharmaceuticals
13.8.1 Hikma Pharmaceuticals Company Information
13.8.2 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Hikma Pharmaceuticals Main Business Overview
13.8.5 Hikma Pharmaceuticals Latest Developments
13.9 Teva Pharmaceuticals
13.9.1 Teva Pharmaceuticals Company Information
13.9.2 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Teva Pharmaceuticals Main Business Overview
13.9.5 Teva Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immunotherapy Drugs for Neuroblastoma Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Immunotherapy Drugs for Neuroblastoma by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Immunotherapy Drugs for Neuroblastoma by Country/Region, 2020, 2024 & 2031
2.2 Immunotherapy Drugs for Neuroblastoma Segment by Type
2.2.1 Dinutuximab
2.2.2 Naxitamab
2.2.3 Other
2.3 Immunotherapy Drugs for Neuroblastoma Sales by Type
2.3.1 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
2.3.2 Global Immunotherapy Drugs for Neuroblastoma Revenue and Market Share by Type (2020-2025)
2.3.3 Global Immunotherapy Drugs for Neuroblastoma Sale Price by Type (2020-2025)
2.4 Immunotherapy Drugs for Neuroblastoma Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Immunotherapy Drugs for Neuroblastoma Sales by Application
2.5.1 Global Immunotherapy Drugs for Neuroblastoma Sale Market Share by Application (2020-2025)
2.5.2 Global Immunotherapy Drugs for Neuroblastoma Revenue and Market Share by Application (2020-2025)
2.5.3 Global Immunotherapy Drugs for Neuroblastoma Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Immunotherapy Drugs for Neuroblastoma Breakdown Data by Company
3.1.1 Global Immunotherapy Drugs for Neuroblastoma Annual Sales by Company (2020-2025)
3.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Company (2020-2025)
3.2 Global Immunotherapy Drugs for Neuroblastoma Annual Revenue by Company (2020-2025)
3.2.1 Global Immunotherapy Drugs for Neuroblastoma Revenue by Company (2020-2025)
3.2.2 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Company (2020-2025)
3.3 Global Immunotherapy Drugs for Neuroblastoma Sale Price by Company
3.4 Key Manufacturers Immunotherapy Drugs for Neuroblastoma Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immunotherapy Drugs for Neuroblastoma Product Location Distribution
3.4.2 Players Immunotherapy Drugs for Neuroblastoma Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA BY GEOGRAPHIC REGION
4.1 World Historic Immunotherapy Drugs for Neuroblastoma Market Size by Geographic Region (2020-2025)
4.1.1 Global Immunotherapy Drugs for Neuroblastoma Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Immunotherapy Drugs for Neuroblastoma Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Immunotherapy Drugs for Neuroblastoma Market Size by Country/Region (2020-2025)
4.2.1 Global Immunotherapy Drugs for Neuroblastoma Annual Sales by Country/Region (2020-2025)
4.2.2 Global Immunotherapy Drugs for Neuroblastoma Annual Revenue by Country/Region (2020-2025)
4.3 Americas Immunotherapy Drugs for Neuroblastoma Sales Growth
4.4 APAC Immunotherapy Drugs for Neuroblastoma Sales Growth
4.5 Europe Immunotherapy Drugs for Neuroblastoma Sales Growth
4.6 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Growth
5 AMERICAS
5.1 Americas Immunotherapy Drugs for Neuroblastoma Sales by Country
5.1.1 Americas Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
5.1.2 Americas Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
5.2 Americas Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
5.3 Americas Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immunotherapy Drugs for Neuroblastoma Sales by Region
6.1.1 APAC Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025)
6.1.2 APAC Immunotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025)
6.2 APAC Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
6.3 APAC Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Immunotherapy Drugs for Neuroblastoma by Country
7.1.1 Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
7.1.2 Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
7.2 Europe Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
7.3 Europe Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma by Country
8.1.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
8.1.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
8.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
8.3 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immunotherapy Drugs for Neuroblastoma
10.3 Manufacturing Process Analysis of Immunotherapy Drugs for Neuroblastoma
10.4 Industry Chain Structure of Immunotherapy Drugs for Neuroblastoma
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immunotherapy Drugs for Neuroblastoma Distributors
11.3 Immunotherapy Drugs for Neuroblastoma Customer
12 WORLD FORECAST REVIEW FOR IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA BY GEOGRAPHIC REGION
12.1 Global Immunotherapy Drugs for Neuroblastoma Market Size Forecast by Region
12.1.1 Global Immunotherapy Drugs for Neuroblastoma Forecast by Region (2026-2031)
12.1.2 Global Immunotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Immunotherapy Drugs for Neuroblastoma Forecast by Type (2026-2031)
12.7 Global Immunotherapy Drugs for Neuroblastoma Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 United Therapeutics
13.1.1 United Therapeutics Company Information
13.1.2 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 United Therapeutics Main Business Overview
13.1.5 United Therapeutics Latest Developments
13.2 Y-mAbs Therapeutics
13.2.1 Y-mAbs Therapeutics Company Information
13.2.2 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Y-mAbs Therapeutics Main Business Overview
13.2.5 Y-mAbs Therapeutics Latest Developments
13.3 EUSA Pharma
13.3.1 EUSA Pharma Company Information
13.3.2 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 EUSA Pharma Main Business Overview
13.3.5 EUSA Pharma Latest Developments
13.4 ANI Pharmaceuticals
13.4.1 ANI Pharmaceuticals Company Information
13.4.2 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 ANI Pharmaceuticals Main Business Overview
13.4.5 ANI Pharmaceuticals Latest Developments
13.5 Baxter Healthcare
13.5.1 Baxter Healthcare Company Information
13.5.2 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Baxter Healthcare Main Business Overview
13.5.5 Baxter Healthcare Latest Developments
13.6 Ingenus Pharmaceuticals
13.6.1 Ingenus Pharmaceuticals Company Information
13.6.2 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Ingenus Pharmaceuticals Main Business Overview
13.6.5 Ingenus Pharmaceuticals Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Hikma Pharmaceuticals
13.8.1 Hikma Pharmaceuticals Company Information
13.8.2 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Hikma Pharmaceuticals Main Business Overview
13.8.5 Hikma Pharmaceuticals Latest Developments
13.9 Teva Pharmaceuticals
13.9.1 Teva Pharmaceuticals Company Information
13.9.2 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
13.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Teva Pharmaceuticals Main Business Overview
13.9.5 Teva Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Immunotherapy Drugs for Neuroblastoma Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Immunotherapy Drugs for Neuroblastoma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Dinutuximab
Table 4. Major Players of Naxitamab
Table 5. Major Players of Other
Table 6. Global Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 7. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Table 8. Global Immunotherapy Drugs for Neuroblastoma Revenue by Type (2020-2025) & ($ million)
Table 9. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2025)
Table 10. Global Immunotherapy Drugs for Neuroblastoma Sale Price by Type (2020-2025) & (US$/Unit)
Table 11. Global Immunotherapy Drugs for Neuroblastoma Sale by Application (2020-2025) & (K Units)
Table 12. Global Immunotherapy Drugs for Neuroblastoma Sale Market Share by Application (2020-2025)
Table 13. Global Immunotherapy Drugs for Neuroblastoma Revenue by Application (2020-2025) & ($ million)
Table 14. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2020-2025)
Table 15. Global Immunotherapy Drugs for Neuroblastoma Sale Price by Application (2020-2025) & (US$/Unit)
Table 16. Global Immunotherapy Drugs for Neuroblastoma Sales by Company (2020-2025) & (K Units)
Table 17. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Company (2020-2025)
Table 18. Global Immunotherapy Drugs for Neuroblastoma Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Company (2020-2025)
Table 20. Global Immunotherapy Drugs for Neuroblastoma Sale Price by Company (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Immunotherapy Drugs for Neuroblastoma Producing Area Distribution and Sales Area
Table 22. Players Immunotherapy Drugs for Neuroblastoma Products Offered
Table 23. Immunotherapy Drugs for Neuroblastoma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Immunotherapy Drugs for Neuroblastoma Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share Geographic Region (2020-2025)
Table 28. Global Immunotherapy Drugs for Neuroblastoma Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Immunotherapy Drugs for Neuroblastoma Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2020-2025)
Table 32. Global Immunotherapy Drugs for Neuroblastoma Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 35. Americas Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2025)
Table 36. Americas Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 38. Americas Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)
Table 39. APAC Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K Units)
Table 40. APAC Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)
Table 41. APAC Immunotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 43. APAC Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)
Table 44. Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 45. Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 47. Europe Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Immunotherapy Drugs for Neuroblastoma
Table 53. Key Market Challenges & Risks of Immunotherapy Drugs for Neuroblastoma
Table 54. Key Industry Trends of Immunotherapy Drugs for Neuroblastoma
Table 55. Immunotherapy Drugs for Neuroblastoma Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Immunotherapy Drugs for Neuroblastoma Distributors List
Table 58. Immunotherapy Drugs for Neuroblastoma Customer List
Table 59. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas Immunotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Immunotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC Immunotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. United Therapeutics Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 74. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 75. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. United Therapeutics Main Business
Table 77. United Therapeutics Latest Developments
Table 78. Y-mAbs Therapeutics Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 79. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 80. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Y-mAbs Therapeutics Main Business
Table 82. Y-mAbs Therapeutics Latest Developments
Table 83. EUSA Pharma Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 84. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 85. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. EUSA Pharma Main Business
Table 87. EUSA Pharma Latest Developments
Table 88. ANI Pharmaceuticals Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 89. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 90. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. ANI Pharmaceuticals Main Business
Table 92. ANI Pharmaceuticals Latest Developments
Table 93. Baxter Healthcare Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 94. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 95. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. Baxter Healthcare Main Business
Table 97. Baxter Healthcare Latest Developments
Table 98. Ingenus Pharmaceuticals Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 99. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 100. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. Ingenus Pharmaceuticals Main Business
Table 102. Ingenus Pharmaceuticals Latest Developments
Table 103. Pfizer Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 104. Pfizer Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 105. Pfizer Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. Pfizer Main Business
Table 107. Pfizer Latest Developments
Table 108. Hikma Pharmaceuticals Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 109. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 110. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111. Hikma Pharmaceuticals Main Business
Table 112. Hikma Pharmaceuticals Latest Developments
Table 113. Teva Pharmaceuticals Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 114. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 115. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. Teva Pharmaceuticals Main Business
Table 117. Teva Pharmaceuticals Latest Developments
Table 1. Immunotherapy Drugs for Neuroblastoma Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Immunotherapy Drugs for Neuroblastoma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Dinutuximab
Table 4. Major Players of Naxitamab
Table 5. Major Players of Other
Table 6. Global Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 7. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Table 8. Global Immunotherapy Drugs for Neuroblastoma Revenue by Type (2020-2025) & ($ million)
Table 9. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2025)
Table 10. Global Immunotherapy Drugs for Neuroblastoma Sale Price by Type (2020-2025) & (US$/Unit)
Table 11. Global Immunotherapy Drugs for Neuroblastoma Sale by Application (2020-2025) & (K Units)
Table 12. Global Immunotherapy Drugs for Neuroblastoma Sale Market Share by Application (2020-2025)
Table 13. Global Immunotherapy Drugs for Neuroblastoma Revenue by Application (2020-2025) & ($ million)
Table 14. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2020-2025)
Table 15. Global Immunotherapy Drugs for Neuroblastoma Sale Price by Application (2020-2025) & (US$/Unit)
Table 16. Global Immunotherapy Drugs for Neuroblastoma Sales by Company (2020-2025) & (K Units)
Table 17. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Company (2020-2025)
Table 18. Global Immunotherapy Drugs for Neuroblastoma Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Company (2020-2025)
Table 20. Global Immunotherapy Drugs for Neuroblastoma Sale Price by Company (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Immunotherapy Drugs for Neuroblastoma Producing Area Distribution and Sales Area
Table 22. Players Immunotherapy Drugs for Neuroblastoma Products Offered
Table 23. Immunotherapy Drugs for Neuroblastoma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Immunotherapy Drugs for Neuroblastoma Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share Geographic Region (2020-2025)
Table 28. Global Immunotherapy Drugs for Neuroblastoma Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Immunotherapy Drugs for Neuroblastoma Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2020-2025)
Table 32. Global Immunotherapy Drugs for Neuroblastoma Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 35. Americas Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2025)
Table 36. Americas Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 38. Americas Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)
Table 39. APAC Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K Units)
Table 40. APAC Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)
Table 41. APAC Immunotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 43. APAC Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)
Table 44. Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 45. Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 47. Europe Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Immunotherapy Drugs for Neuroblastoma
Table 53. Key Market Challenges & Risks of Immunotherapy Drugs for Neuroblastoma
Table 54. Key Industry Trends of Immunotherapy Drugs for Neuroblastoma
Table 55. Immunotherapy Drugs for Neuroblastoma Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Immunotherapy Drugs for Neuroblastoma Distributors List
Table 58. Immunotherapy Drugs for Neuroblastoma Customer List
Table 59. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas Immunotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Immunotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC Immunotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Immunotherapy Drugs for Neuroblastoma Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global Immunotherapy Drugs for Neuroblastoma Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. United Therapeutics Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 74. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 75. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. United Therapeutics Main Business
Table 77. United Therapeutics Latest Developments
Table 78. Y-mAbs Therapeutics Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 79. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 80. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Y-mAbs Therapeutics Main Business
Table 82. Y-mAbs Therapeutics Latest Developments
Table 83. EUSA Pharma Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 84. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 85. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. EUSA Pharma Main Business
Table 87. EUSA Pharma Latest Developments
Table 88. ANI Pharmaceuticals Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 89. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 90. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. ANI Pharmaceuticals Main Business
Table 92. ANI Pharmaceuticals Latest Developments
Table 93. Baxter Healthcare Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 94. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 95. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. Baxter Healthcare Main Business
Table 97. Baxter Healthcare Latest Developments
Table 98. Ingenus Pharmaceuticals Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 99. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 100. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. Ingenus Pharmaceuticals Main Business
Table 102. Ingenus Pharmaceuticals Latest Developments
Table 103. Pfizer Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 104. Pfizer Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 105. Pfizer Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. Pfizer Main Business
Table 107. Pfizer Latest Developments
Table 108. Hikma Pharmaceuticals Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 109. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 110. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111. Hikma Pharmaceuticals Main Business
Table 112. Hikma Pharmaceuticals Latest Developments
Table 113. Teva Pharmaceuticals Basic Information, Immunotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors
Table 114. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
Table 115. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. Teva Pharmaceuticals Main Business
Table 117. Teva Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Immunotherapy Drugs for Neuroblastoma
Figure 2. Immunotherapy Drugs for Neuroblastoma Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immunotherapy Drugs for Neuroblastoma Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Immunotherapy Drugs for Neuroblastoma Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2024)
Figure 10. Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Dinutuximab
Figure 12. Product Picture of Naxitamab
Figure 13. Product Picture of Other
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type in 2025
Figure 15. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2025)
Figure 16. Immunotherapy Drugs for Neuroblastoma Consumed in Hospital
Figure 17. Global Immunotherapy Drugs for Neuroblastoma Market: Hospital (2020-2025) & (K Units)
Figure 18. Immunotherapy Drugs for Neuroblastoma Consumed in Clinic
Figure 19. Global Immunotherapy Drugs for Neuroblastoma Market: Clinic (2020-2025) & (K Units)
Figure 20. Immunotherapy Drugs for Neuroblastoma Consumed in Other
Figure 21. Global Immunotherapy Drugs for Neuroblastoma Market: Other (2020-2025) & (K Units)
Figure 22. Global Immunotherapy Drugs for Neuroblastoma Sale Market Share by Application (2024)
Figure 23. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application in 2025
Figure 24. Immunotherapy Drugs for Neuroblastoma Sales by Company in 2025 (K Units)
Figure 25. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Company in 2025
Figure 26. Immunotherapy Drugs for Neuroblastoma Revenue by Company in 2025 ($ millions)
Figure 27. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Company in 2025
Figure 28. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Immunotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)
Figure 31. Americas Immunotherapy Drugs for Neuroblastoma Revenue 2020-2025 ($ millions)
Figure 32. APAC Immunotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)
Figure 33. APAC Immunotherapy Drugs for Neuroblastoma Revenue 2020-2025 ($ millions)
Figure 34. Europe Immunotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)
Figure 35. Europe Immunotherapy Drugs for Neuroblastoma Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)
Figure 37. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue 2020-2025 ($ millions)
Figure 38. Americas Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2025
Figure 39. Americas Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)
Figure 40. Americas Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Figure 41. Americas Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 42. United States Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region in 2025
Figure 47. APAC Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)
Figure 48. APAC Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Figure 49. APAC Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 50. China Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 54. India Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2025
Figure 58. Europe Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)
Figure 59. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Figure 60. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 61. Germany Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 62. France Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 69. Egypt Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Immunotherapy Drugs for Neuroblastoma in 2025
Figure 75. Manufacturing Process Analysis of Immunotherapy Drugs for Neuroblastoma
Figure 76. Industry Chain Structure of Immunotherapy Drugs for Neuroblastoma
Figure 77. Channels of Distribution
Figure 78. Global Immunotherapy Drugs for Neuroblastoma Sales Market Forecast by Region (2026-2031)
Figure 79. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Immunotherapy Drugs for Neuroblastoma
Figure 2. Immunotherapy Drugs for Neuroblastoma Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immunotherapy Drugs for Neuroblastoma Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Immunotherapy Drugs for Neuroblastoma Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2024)
Figure 10. Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Dinutuximab
Figure 12. Product Picture of Naxitamab
Figure 13. Product Picture of Other
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type in 2025
Figure 15. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2025)
Figure 16. Immunotherapy Drugs for Neuroblastoma Consumed in Hospital
Figure 17. Global Immunotherapy Drugs for Neuroblastoma Market: Hospital (2020-2025) & (K Units)
Figure 18. Immunotherapy Drugs for Neuroblastoma Consumed in Clinic
Figure 19. Global Immunotherapy Drugs for Neuroblastoma Market: Clinic (2020-2025) & (K Units)
Figure 20. Immunotherapy Drugs for Neuroblastoma Consumed in Other
Figure 21. Global Immunotherapy Drugs for Neuroblastoma Market: Other (2020-2025) & (K Units)
Figure 22. Global Immunotherapy Drugs for Neuroblastoma Sale Market Share by Application (2024)
Figure 23. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application in 2025
Figure 24. Immunotherapy Drugs for Neuroblastoma Sales by Company in 2025 (K Units)
Figure 25. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Company in 2025
Figure 26. Immunotherapy Drugs for Neuroblastoma Revenue by Company in 2025 ($ millions)
Figure 27. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Company in 2025
Figure 28. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Immunotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)
Figure 31. Americas Immunotherapy Drugs for Neuroblastoma Revenue 2020-2025 ($ millions)
Figure 32. APAC Immunotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)
Figure 33. APAC Immunotherapy Drugs for Neuroblastoma Revenue 2020-2025 ($ millions)
Figure 34. Europe Immunotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)
Figure 35. Europe Immunotherapy Drugs for Neuroblastoma Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)
Figure 37. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue 2020-2025 ($ millions)
Figure 38. Americas Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2025
Figure 39. Americas Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)
Figure 40. Americas Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Figure 41. Americas Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 42. United States Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region in 2025
Figure 47. APAC Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)
Figure 48. APAC Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Figure 49. APAC Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 50. China Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 54. India Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2025
Figure 58. Europe Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)
Figure 59. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Figure 60. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 61. Germany Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 62. France Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Figure 69. Egypt Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Immunotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Immunotherapy Drugs for Neuroblastoma in 2025
Figure 75. Manufacturing Process Analysis of Immunotherapy Drugs for Neuroblastoma
Figure 76. Industry Chain Structure of Immunotherapy Drugs for Neuroblastoma
Figure 77. Channels of Distribution
Figure 78. Global Immunotherapy Drugs for Neuroblastoma Sales Market Forecast by Region (2026-2031)
Figure 79. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share Forecast by Application (2026-2031)
